The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a huge mover today! The stock decreased 3.20% or $0.2 during the last trading session, reaching $6.05. About 235,944 shares traded. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has declined 38.80% since May 17, 2017 and is downtrending. It has underperformed by 50.35% the S&P500.The move comes after 9 months negative chart setup for the $345.71 million company. It was reported on May, 17 by Barchart.com. We have $5.57 PT which if reached, will make NASDAQ:CRBP worth $27.66M less.
ANDIAMO CORPORATION (OTCMKTS:ANDI) had an increase of 350.97% in short interest. ANDI’s SI was 626,400 shares in May as released by FINRA. Its up 350.97% from 138,900 shares previously. The stock decreased 7.50% or $0.0003 during the last trading session, reaching $0.0037. About 4.99 million shares traded. Andiamo Corporation (OTCMKTS:ANDI) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Andiamo Corporation, through its subsidiaries, provides prepackaged software services. The company has market cap of $549. It provides mobile applications through the Apple iTunes App Store and the Google Android market in approximately 80 countries. It currently has negative earnings. The firm was formerly known as Title Consulting Services, Inc. and changed its name to Andiamo Corporation in June 2011.
Analysts await Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) to report earnings on August, 8. They expect $-0.18 earnings per share, down 20.00% or $0.03 from last year’s $-0.15 per share. After $-0.21 actual earnings per share reported by Corbus Pharmaceuticals Holdings, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth.
More notable recent Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) news were published by: Seekingalpha.com which released: “Corbus: Revisiting This ~$5 Biotech Concern” on May 15, 2018, also Profitconfidential.com with their article: “This Is What Is Worth Watching on the CRBP Stock Chart” published on May 16, 2018, Nasdaq.com published: “Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting” on May 15, 2018. More interesting news about Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) were released by: Prnewswire.com and their article: “Cannabis is Fueling the Next Era of Medical Revolution” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update” with publication date: May 10, 2018.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company has market cap of $345.71 million. The Company’s lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. It currently has negative earnings.